Le sécukinumab améliore la fonction physique et la qualité de vie et inhibe les dommages structurels chez les patients PsA avec rémission soutenue ou faible activité de la maladie : Résultats de l'étude de phase 3 FUTURE 5 d'une durée de 2 ans

RMD Open 2023;9:e002939 doi 10.1136/rmdopen-2022-002939

Results from the 2-year phase 3 study FUTURE 5 show that the majority of patients with PsA who are treated with secukinumab were able to achieve sustained low disease activity or remission by week 104.

There is currently a limited understanding of the proportion of patients with PsA who achieve long term low disease activity or remission through treatment with secukinumab. Data from this study may reinforce the use of the Minimal Disease Activity index and the Disease Activity Index for Psoriatic Arthritis as treatment goals in PsA, as their achievement in this study has led to benefits in health-related quality of life and physical function.